{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:37:40Z","timestamp":1761896260319},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.acuro.2015.12.009","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T07:46:44Z","timestamp":1456386404000},"page":"370-377","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Estudio retrospectivo de diferentes opciones de tratamiento conservador con Bacilo de Calmette-Gu\u00e8rin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento"],"prefix":"10.1016","volume":"40","author":[{"given":"J.","family":"Palou-Redorta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Solsona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Madero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Unda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Mart\u00ednez-Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Portillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Chantada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Moyano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2015.12.009_bib0180","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)36724-1","article-title":"Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy","volume":"148","author":"Cookson","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0185","series-title":"European Association of Urology guidelines on non-muscle invasive (TaT1) bladder cancer","author":"Babjuk","year":"2015"},{"key":"10.1016\/j.acuro.2015.12.009_bib0190","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0022-5347(05)65969-1","article-title":"Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy","volume":"166","author":"Dutta","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0195","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival","volume":"169","author":"Shahin","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0200","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0205","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumour progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2015.12.009_bib0210","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0215","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: A combined analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0220","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0225","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0230","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2015.12.009_bib0235","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.eursup.2010.08.005","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin: The standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle invasive bladder cancer","volume":"9","author":"Lamm","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.acuro.2015.12.009_bib0240","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients withsuperficial bladder cancer: Results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2015.12.009_bib0245","author":"Brausi","year":"2013","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2015.12.009_bib0250","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.eururo.2008.06.062","article-title":"Is maintenance bacillus Calmette-Gu\u00e9rin really necessary?","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0255","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Club Urol\u00f3gico Espa\u00f1ol de Tratamiento Oncol\u00f3gico (CUETO): Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: Multivariate analysis of data from 4 randomized CUETO trials","volume":"53","author":"Fern\u00e1ndez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0260","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1464-410X.2010.09572.x","article-title":"Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Gu\u00e9rin treatment","volume":"107","author":"Kakiashvili","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2015.12.009_bib0265","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.urology.2006.09.019","article-title":"Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by bacille Calmette-Gu\u00e9rin immunotherapy","volume":"69","author":"Margel","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2015.12.009_bib0270","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0275","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of non-muscle invasive bladder cancer (NMIBC) by the International Bladder Cancer Group (IBCG)","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0280","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0285","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"for CUETO (Club Urol\u00f3gico Espa\u00f1ol de Tratamiento Oncol\u00f3gico): Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez- Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2015.12.009_bib0290","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","volume":"174","author":"Martinez- Pi\u00f1eiro","year":"2005","journal-title":"J Uro"},{"key":"10.1016\/j.acuro.2015.12.009_bib0295","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.acuro.2015.12.009_bib0300","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2015.12.009_bib0305","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0310","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","article-title":"The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy","volume":"100","author":"Lambert","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2015.12.009_bib0315","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","article-title":"Primary T1G3 bladder cancer: Organ preserving approach or immediate cystectomy?","volume":"172","author":"Thalmann","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0320","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","article-title":"An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer","volume":"57","author":"Kulkarni","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0325","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0330","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","article-title":"Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy","volume":"22","author":"Bianco","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0335","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.eururo.2009.07.005","article-title":"Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer","volume":"56","author":"Dalbagni","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0340","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.eururo.2003.11.007","article-title":"T1G3 bladder tumours: The case for radical cystectomy","volume":"45","author":"Malavaud","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2015.12.009_bib0345","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.acuro.2012.03.011","article-title":"La re-resecci\u00f3n transuretral puede no ser necesaria en todos los tumores vesical no m\u00fasculo invasivos de alto grado","volume":"36","author":"Gaya","year":"2012","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.acuro.2015.12.009_bib0350","article-title":"The impact of Re-TUR on clinical outcomes in a large multicenter cohort of T1 HG\/G3 patients treated with BCG","author":"Gontero","year":"2015","journal-title":"Eur Urol"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480616000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480616000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T23:56:29Z","timestamp":1567641389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480616000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0210480616000048"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2015.12.009","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estudio retrospectivo de diferentes opciones de tratamiento conservador con Bacilo de Calmette-Gu\u00e8rin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2015.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}